Hence, it appears that the downregulation of NLRC5 and MHC-I in cancer cells could be a part of the global genetic de-differentiation program that accompanies progressive cancer growth in order to maintain the cancer initiating cell population rather than an immune escape program. The gene discussed is NLRC5; the disease is cancer.